文献速递外周动脉疾病

外周动脉疾病患者接受血管内血运重建、开放手术或一期大截肢初始治疗的成本分析

Cost Analysis of Initial Treatment With Endovascular Revascularization, Open Surgery, or Primary Major Amputation in Patients With Peripheral Artery Disease.
PubMed 文献 · J Endovasc Ther · 2018-05-14

该多中心回顾性分析纳入1138例外周动脉疾病患者,比较2013至2016年间血管内血运重建(1017例)、开放手术(86例)和一期大截肢(35例)的初始治疗总费用。校正混杂因素后,血管内血运重建组每次入院平均费用为18396澳元(95%CI 16436至20356),显著低于开放手术组的31908澳元(95%CI 28285至35530)和大截肢组的43033澳元(95%CI 37706至48361)(p<0.001)。结论认为血管内血运重建虽然器械费用较高,但因住院天数和ICU使用减少,整体费用低于开放手术和一期截肢。

要点

  • 血管内血运重建组住院时间3.4天、ICU时间2.4小时,均少于开放手术组(10.0天、22.6小时)和大截肢组(20.2天、54.6小时)(p<0.01)。
  • 血管内组假体和器械费用较高(2770澳元 vs 开放手术1658澳元、截肢1219澳元,p<0.01),但总费用仍显著更低。
  • 校正混杂因素后,血管内组每次入院平均费用18396澳元,显著低于开放手术31908澳元和一期大截肢43033澳元(p<0.001)。

核心结论

  • 在外周动脉疾病患者中,血管内血运重建的初始治疗费用低于开放手术和一期大截肢。
  • 虽然当代血管内治疗所用器械更昂贵,但住院天数、ICU使用及相关医院资源的减少使每次入院平均总费用显著更低。

研究设计与样本

  • 多中心回顾性分析,纳入1138例有症状的外周动脉疾病患者,2013至2016年间共接受1017例血管内手术、86例开放手术和35例大截肢。
  • 基于选定诊断相关组生成的患者个体数据进行成本组合分析,平均费用以95%置信区间(CI)表示。

主要发现

  • 截肢组急诊手术比例(68.6% vs 血管内组13.3% vs 开放手术组27.9%,p<0.001)和严重肢体缺血比例(88.6% vs 35.9% vs 37.2%,p<0.001)均高于血管内治疗组和开放手术组。
  • 血管内血运重建组住院时间(3.4 vs 开放手术10.0 vs 大截肢20.2天,p<0.01)和ICU使用时间(2.4 vs 22.6 vs 54.6小时,p<0.01)均少于开放手术组和大截肢组。
  • 血管内组假体和器械平均费用较高(2770澳元 vs 开放手术1658澳元、截肢1219澳元,p<0.01)。
  • 校正混杂因素后,血管内血运重建组每次入院平均费用为18396澳元(95%CI 16436至20356),显著低于开放手术组的31908澳元(95%CI 28285至35530)和大截肢组的43033澳元(95%CI 37706至48361)(p<0.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To compare the total initial treatment costs for open surgery, endovascular revascularization, and primary major amputation within a single-payer healthcare system. METHODS: A multicenter, retrospective analysis was undertaken to evaluate 1138 patients with symptomatic peripheral artery disease (PAD) who underwent 1017 endovascular procedures, 86 open surgeries, and 35 major amputations between 2013 and 2016. A cost-mix analysis was performed on individual patient data generated for selected diagnosis-related groups. Mean costs are presented with the 95% confidence interval (CI). RESULTS: There was no intergroup difference in demographics or private health insurance status. However, the amputation group had a higher proportion of emergency procedures (68.6% vs 13.3% vs 27.9%, p<0.001) and critical limb ischemia (88.6% vs 35.9% vs 37.2%, p<0.001) compared with the endovascular therapy and open surgery groups, respectively. The endovascular revascularization group spent less time in hospital and used fewer intensive care unit (ICU) resources compared with the open surgery and major amputation groups (hospital length of stay: 3.4 vs 10.0 vs 20.2 days, p<0.01; ICU: 2.4 vs 22.6 vs 54.6 hours, p<0.01), respectively. While mean prosthetic and device costs were higher in the endovascular group [AUD$2770 vs AUD$1658 (open) and AUD$1219 (amputation), p<0.01], substantial disparities were observed in costs associated with longer operating theater times, length of stay, and ICU utilization, which resulted in significantly higher costs in the open and amputation groups. After adjusting for confounders, the AUD$18,396 (95% CI AUD$16,436 to AUD$20,356) mean cost per admission for the endovascular revascularization group was significantly less (p<0.001) than the open surgery (AUD$31,908, 95% CI AUD$28,285 to AUD$35,530) and major amputation groups (AUD$43,033, 95% CI AUD$37,706 to AUD$48,361). CONCLUSION: Endovascular revascularization procedures for PAD cost the health payer less compared with open surgery and primary amputation. While devices used to deliver contemporary endovascular therapy are more expensive, the reduction in bed days, ICU utilization, and related hospital resources results in a significantly lower mean total cost per admission for the initial treatment.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Tang L, Paravastu SCV, Thomas SD, et al. Cost Analysis of Initial Treatment With Endovascular Revascularization, Open Surgery, or Primary Major Amputation in Patients With Peripheral Artery Disease. J Endovasc Ther. 2018. PMID: 29756521. doi:10.1177/1526602818774786

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。